UNSPSC 51202418: Siltuximab

An interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

UNSPSC 51202418 Siltuximab is a Commodity code nominally identifying a specific biologic therapeutic agent, but recent state and local opportunities tagged under this code show little alignment with the code's stated scope. The actual procurement activity reflects a broader pharmaceutical and medical supply sourcing strategy across health departments, fire rescue services, and cooperative purchasing alliances, rather than procurement of siltuximab itself. State and local governments are using this code to solicit generic pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and emergency medical supplies through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire rescue divisions (City of Tampa), and multistate cooperative purchasing alliances (Minnesota MMCAP). The code's application appears to serve as a catch-all for pharmaceutical and medical commodity procurement rather than a precision classifier for siltuximab specifically.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the most recent high-value and formal solicitations centered in the Midwest and South. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with an estimated contract value of $700,000 for Tampa Fire Department supplies; the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities with a two-year term and optional extensions; and the Texas HHS Request for Information HHS0017013 (posted April 3, 2026, due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Tampa procurement is sheltered for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The code's mismatch with actual procurement scope suggests vendors should verify code alignment before pursuing opportunities and monitor whether state and local procurement offices intend to refine classification or continue using this commodity code as a pharmaceutical sourcing umbrella.